Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Company wins court ruling to continue development of Michigan factory serving EV industry
GREEN TOWNSHIP, Mich. (AP) — A judge has ordered a Michigan community to stop blocking efforts to br2024-05-21- (ECNS) -- China has built 3.377 million 5G base stations, covering all prefecture-level and county-l2024-05-21
Mideast in Pictures: Long road to recovery awaits quake
People pass by a collapsed building in Adiyaman, Türkiye, Feb. 18, 2023. (Photo by Mustafa Kaya/Xinh2024-05-21Adams, Reyna, Turner, Ream are US concerns ahead of Copa America
NEW YORK (AP) — Tyler Adams, Gio Reyna, Matt Turner and Tim Ream will be given the three weeks ahead2024-05-21With secret contract, U.S. uses spyware to supervise world: NYT
This photo taken on Feb. 3, 2023 shows the White House in Washington, D.C., the United States. (Xinh2024-05-21
atest comment